He blames a 49ers game day for the uptick, reports no negative side effects so far, and says food noise keeps fading.
Recap by typeshit. Video by @fat.chief on TikTok.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
Investseekers shares notes on the upcoming French rollout of the Wegovy pill and where Novo Nordisk might launch it next in Europe.
A short social clip runs through the daily checklist of a GLP-1 routine: injections, water, protein and keeping tabs on progress.
Loading…